Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ. Taal W, et al. Among authors: walenkamp am. Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15. Lancet Oncol. 2014. PMID: 25035291 Clinical Trial.
Value of 11C-methionine PET in imaging brain tumours and metastases.
Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, Slart RH. Glaudemans AW, et al. Among authors: walenkamp am. Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):615-35. doi: 10.1007/s00259-012-2295-5. Epub 2012 Dec 12. Eur J Nucl Med Mol Imaging. 2013. PMID: 23232505 Review.
The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
Dirven L, van den Bent MJ, Bottomley A, van der Meer N, van der Holt B, Vos MJ, Walenkamp AM, Beerepoot LV, Hanse MC, Reijneveld JC, Otten A, de Vos FY, Smits M, Bromberg JE, Taal W, Taphoorn MJ; Dutch Neuro-Oncology Group (LWNO). Dirven L, et al. Among authors: walenkamp am. Eur J Cancer. 2015 Jul;51(10):1321-30. doi: 10.1016/j.ejca.2015.03.025. Epub 2015 Apr 17. Eur J Cancer. 2015. PMID: 25899986 Clinical Trial.
Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
Beije N, Kraan J, Taal W, van der Holt B, Oosterkamp HM, Walenkamp AM, Beerepoot L, Hanse M, van Linde ME, Otten A, Vernhout RM, de Vos FY, Gratama JW, Sleijfer S, van den Bent MJ. Beije N, et al. Among authors: walenkamp am. Br J Cancer. 2015 Jul 14;113(2):226-31. doi: 10.1038/bjc.2015.191. Epub 2015 Jun 4. Br J Cancer. 2015. PMID: 26042933 Free PMC article. Clinical Trial.
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.
den Hollander MW, Bensch F, Glaudemans AW, Oude Munnink TH, Enting RH, den Dunnen WF, Heesters MA, Kruyt FA, Lub-de Hooge MN, Cees de Groot J, Pearlberg J, Gietema JA, de Vries EG, Walenkamp AM. den Hollander MW, et al. Among authors: walenkamp am. J Nucl Med. 2015 Sep;56(9):1310-4. doi: 10.2967/jnumed.115.154401. Epub 2015 Jul 1. J Nucl Med. 2015. PMID: 26135113 Free article. Clinical Trial.
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, Böttcher R, Gao Y, de Wit M, Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, van der Holt B, Vernhout RM, Sillevis Smitt PA, Kros JM, French PJ. Erdem-Eraslan L, et al. Cancer Res. 2016 Feb 1;76(3):525-34. doi: 10.1158/0008-5472.CAN-15-0776. Epub 2016 Jan 13. Cancer Res. 2016. PMID: 26762204 Clinical Trial.
Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study.
Brahm CG, den Hollander MW, Enting RH, de Groot JC, Solouki AM, den Dunnen WFA, Heesters MAAM, Wagemakers M, Verheul HMW, de Vries EGE, Pruim J, Walenkamp AME. Brahm CG, et al. Among authors: walenkamp ame. Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2404-2412. doi: 10.1007/s00259-018-4090-4. Epub 2018 Jul 21. Eur J Nucl Med Mol Imaging. 2018. PMID: 30032322 Free PMC article. Clinical Trial.
113 results